AU: ACCC pakt vermoedelijk misleidende Nurofen claims aan

30 maart 2015

The Australian Competition and Consumer Commission (ACCC) has instituted proceedings in the Federal Court of Australia against Reckitt Benckiser (Australia) Pty Ltd (Reckitt Benckiser), alleging that it made false or misleading claims that its Nurofen Specific Pain Products were each formulated to treat a specific kind of pain, when the products are identical and each contain the same active ingredient, ibuprofen lysine 342mg.
The ACCC is seeking declarations, injunctions, an order for the publication of corrective notices, penalties and costs. This matter is listed for a case management conference on 31 March 2015 in the Federal Court of Australia in Sydney (ACCC Mediabericht, 5 maart 2015).
Klik hier voor het volledige mediabericht.
Klik hier voor meer informatie over Pharmaceutical packaging regulations - Module of NVC E-Course Pharmaceutical Packaging (online, in het Engels).

Heeft u vragen over dit onderwerp, neem dan contact met ons op via e-mail of bel: +31-(0)182-512411. Dit bericht is ook opgenomen in ons maandelijkse overzicht, de NVC Members-only Update.